In the United States, medical marijuana is now legal in 29 states. Not only that, but the recreational use of marijuana is now legal in 10 states. You can walk into a licensed store in places like California, Oregon and Colorado and purchase cannabis nearly as easily as buying beer.
Similar dynamics are taking place in Canada. Medical marijuana consumption was first legalized in 2001, and in 2017 legislation paved the way for the legalization of recreational use throughout all of Canada — a development that’s expected to be implemented in the summer of this year.
We analyzed data from Priceonomics customer Wikileaf, a company that tracks cannabis prices at dispensaries across the US and Canada and aggregated the data at the national level and find out the answers.
We discovered that cannabis is 30% less expensive in Canada than the United States. When you look at different cities, the price differential can be even more pronounced. Legal marijuana is 39% cheaper in Vancouver than San Francisco, for example.
Across dispensaries tracked by Wikileaf in the United States, the price of an eighth of marijuana is $40.0, compared to $27.9 in Canada, where it is 30% cheaper.
Read more at Priceonomics
Psychoactive drugs chemically alter the brain and change the way we feel, think, perceive and understand our world.
We are in a psychoactive drug epidemic in our country, most notably the opioids, because of their tragic death toll.
Here are nine things that matter when it comes to drugs:
1. Age. It’s one thing to start drinking or smoking dope when you are 21. It is very different when at 12 or 13 or 15, even 18.
2. Set. Set means the unique biological, neurological, psychological and experiential qualities of the user. Set creates a personal vulnerability and selective responsivity do substances.
3. Route of Administration. How fast a substance gets to and bathes our neurons with its receptor-loving chemical configuration makes a big difference.
Continue Reading at Scientific America
A low unemployment rate and the spreading legalization of marijuana have led many businesses to rethink their drug testing policies for the first time in decades. A small but increasing number are simply no longer testing for pot.
“There is a lot of conflict there, and many employers, they just don’t know what to do,” said Kathryn Russo, a lawyer at Melville, New York-based firm Jackson Lewis. Recreational marijuana use is legal in nine states plus Washington, D.C., and medical marijuana is legal in 29 states.
Here are some questions small businesses need to consider when deciding on what drug testing policies to follow:
– IS IT A FEDERALLY REGULATED POSITION, OR SAFETY-SENSITIVE?
If your business is regulated by the federal Department of Transportation or is a defense contractor, you are likely legally required to drug test for all drugs illegal at the federal level, including marijuana.
– DON’T DISCRIMINATE
In states where medical marijuana is legal, small businesses increasingly risk running into legal trouble if they deny a job to someone who has obtained a medical marijuana prescription.
Read more at Eyewitness News
Chewing betel nut isn’t as common here as it used to be and, to my knowledge, not many people here chew it with tobacco leaves as they do in southeast Asia. There, many users are addicted to that combination, which can create a sense of euphoria and alertness. Strangely enough, scientists at the University of Florida have found that compounds derived from betel nut could help cigarette smokers and betel nut chewers kick their habits.
The researchers say the two addictions share many traits and they want to develop drugs that target both. They’re studying compounds from the areca nut (the scientific name of betel is Areca catechu) to make new molecules that work better than existing smoking-cessation drugs.
“Some new findings say that things we know are bad for our health may actually be helpful. The first bad boy? Chewing betel nut.”
A drug that helps with two different kinds of addiction is really a good thing, but here’s one for you: What if eating chocolate helped prevent and treat diabetes? “Yeah, right!” you say.
Read more at Post Guam
The Trump administration’s proposed tariffs on thousands of Chinese-manufactured products would target dozens of key products used by drug makers, as well as medical devices including pacemakers and artificial joints.
More than 80 percent of the ingredients used to make U.S.-consumed drugs are produced outside of the country, according to the Food and Drug Administration. China, along with India, accounts for most of the bulk ingredients and the FDA has called China a “major provider.”
For brand-name drugs, raw ingredients used by manufacturers are typically a tiny fraction of the cost of a product. They can be more important for generic medications that are essentially low-cost commodity products.
President Trump’s opioid response plan might have multiple prongs, but when he unveiled it Monday, he clearly was most interested in the prong that gets “very tough” on drug dealers. We know this because he said so approximately 5,000 times during a speech announcing the new plan in New Hampshire, a state chosen as the backdrop because it is one of those hardest hit by opioid addiction and overdose deaths.
Trump’s get-tough approach is little more than a reboot of the failed “War on Drugs” from the 1980s, in which the federal government spent enormous sums trying — and failing — to stop the crack cocaine crisis by throwing people in prison, a disproportionate amount of whom were African American and Latino.
His first speech on the topic in October, while vague, promised action on this “public health emergency.” A few days later the commission he convened to study the problem and come up with evidence-based solutions released a 131-page report with 56 recommendations, none of which suggested killing people.
Read the full article in Los Angeles Times
New research on the evolutionary genetics of fungi reveals that the compound that makes some mushrooms ‘magic’ may have evolved as a defensive mechanism to discourage invertebrates from eating them.
Psilocybin occurs in a diverse group of fungi, with genetic analysis indicating that it may have evolved several times. This led a group of researchers from the Ohio State University in the US to suspect that a mechanism known as horizontal gene transfer may be occurring.
Horizontal gene transfer involves the movement of genetic material between species, carried by mobile cells such as bacteriophages. It is a process associated with stressful environments, and is rare in complex multicellular organisms.
Researchers found that distantly related fungi in dung and decaying-wood niches showed less variation in their genome content than close relatives in alternative niches. This suggest that the genomes are shaped in part by shared ecological pressures.
It appears that the biological niche of the psilocybin-containing mushrooms provides a clue. In humans, psilocybin causes profound altered states of consciousness and other symptoms such as increased heart rate and dilated pupils.
Read more at Cosmos Magazine
“Magic” mushrooms seem to have passed their genes for mind-altering substances around among distant species as a survival mechanism: By making fungus-eating insects “trip,” the bugs become less hungry — and less likely to feast on mushrooms.
The researchers studied a group of mushrooms that all produce psilocybin — the chemical agent that causes altered states of consciousness in human beings — but aren’t closely related. The scientists found that the clusters of genes that caused the ‘shrooms to fill themselves with psilocybin were very similar to one another, more similar even than clusters of genes found in closely related species of mushrooms.
HGT isn’t really one process, as the biologist Alita Burmeister explained in the journal Evolution, Medicine and Public Health in 2015. Instead, it’s the term for a group of more or less well-understood processes — like viruses picking up genes from one species and dropping them in another — that can cause groups of genes to jump between species.
The researchers suggested — but didn’t claim to prove — that the crisis in this case was droves of insects feasting on the defenseless mushrooms. Most of the species the scientists studied grew on animal dung and rotting wood — insect-rich environments (and environments full of opportunities to perform HGT). Psilocybin, the scientists wrote, might suppress insects’ appetites or otherwise induce the bugs to stop munching quite so much mush’.